AlphAIAlphAI — Financial news for AI agents
investing.com$HIMS

Canaccord reiterates Hims & Hers stock rating after Q3 results

Canaccord reiterated a Buy rating and $40 price target for Hims & Hers (HIMS) after Q3 results. Revenue met estimates, but adjusted EBITDA fell short. International revenue quadrupled, while U.S. revenue grew 21% YoY. Subscribers declined due to reduced marketing. The company guided Q4 revenue and EBITDA below consensus. Needham lowered its price target to $32 but kept a Buy rating. HIMS reported $890.4M revenue, a 49% YoY increase, but missed EPS expectations with a loss of $0.14 per share.

Original reporting
investing.com
Published Nov 10, 2026, 10:52 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 10:58 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$HIMS
Bearish
high confidence
Mentioned
$HIMS
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$HIMSBearishMed
01

Why it matters

The earnings miss and lowered guidance are likely to drive short‑term downside pressure, though long‑term growth prospects remain positive.

02

Market read

Primary earnings news for HIMS with actionable implications for traders.

03

What to watch

Weight‑loss product pipeline and testosterone revenue ramp may improve margins later in the year.

Relevance 7/10Novelty 7/10Timing: after-hours reaction

Background

Hims & Hers Health (NYSE:HIMS) released its Q3 2026 earnings, showing revenue growth but a miss on adjusted EBITDA, prompting analyst rating reiterations and target adjustments.

Company-level read

Ticker impact

$HIMSBearishHigh confidence
Context

Canaccord reiterated a Buy rating with a $40 price target after Hims & Hers reported Q3 revenue in line with guidance but missed adjusted EBITDA expectations.

Expected impact

likely downside as the market prices in the EBITDA shortfall and reduced target.

Evidence & confidence

The miss on adjusted EBITDA and the downgrade of the price target from $42 to $32 by Needham, combined with a lower guidance, provide a concrete catalyst for a short-term pullback.

Market effects

Sector

Telehealth sector may see broader scrutiny as peers' earnings are evaluated against Hims & Hers' performance.

Regional

U.S. market may see modest pressure on health‑tech stocks.

Global

Limited to investors focused on U.S. listed telehealth companies.

Counterpoint

What could challenge this read

The strong international revenue growth and upcoming product launches could offset short‑term earnings weakness.

Key entities

  • analyst
    Canaccord Genuity

    Reiterated Buy rating with $40 price target.

  • analyst
    Needham

    Reduced price target to $32 while maintaining Buy rating.

Read at source← All news

StoryHims & Hers posts 49% revenue growth but margin collapse and cuts 2026 guidance

Also covered by

5 outlets

Related articles

$HIMSMed

HIMS May See Heightened ‘Gyrations’ As Weight-Loss Drug Trends Fuel Subscriber Uncertainty, Jefferies Warns – Stock Hits 7-Month Lows

Hims & Hers Health (HIMS) shares fell 15% after Q3 earnings missed expectations, with subscribers declining sequentially. Jefferies lowered its price target to $24, citing volatility from weight-loss drug trends. Needham reduced its target to $32 but kept a 'Buy' rating. The company reported a Q3 loss and cut its FY2026 EBITDA and revenue guidance.

finance.yahoo.com
$HIMSHighAI 8/10

Hims & Hers Stock Falls 15% on Weak Q4 Revenue Outlook

Hims & Hers Health (HIMS) shares dropped 15% after the company issued Q4 revenue guidance below expectations, forecasting $875M–$895M vs. analysts' $955.1M estimate. Q3 revenue grew 49% to $890.4M but gross margin declined to 57% from 74%. The company also faces regulatory challenges over weight-loss medications and data privacy.

grafa.com
$HIMSHighAI 8/10

Hims & Hers cuts 2026 earnings outlook despite 49% revenue growth

Hims & Hers Health (HIMS) reported 49% revenue growth in Q3, but lowered its 2026 adjusted EBITDA forecast to $257M-$277M. Revenue guidance was tightened to $3.13B-$3.15B, with Q4 sales expected at $875M-$895M. International revenue surged 321%, while gross margin contracted to 57% from 74%. The company reported a net loss of $33M, with adjusted EBITDA margin falling to 9% from 13%.

finance.yahoo.com